Nobel prize-winning autophagy research using Nilotinib for Parkinson’s
 

The results exceeded our expectations, providing both molecular and clinical evidence that nilotinib may benefit these patients.

Soon we will begin recruiting participants for two phase II trials to test data safety and efficacy. One trial will focus on Parkinson’s and the other on Alzheimer’s. We are also preparing a phase IIa clinical study with nilotinib in Lou Gehrig’s disease and bosutinib in a phase I study. Another cancer drug, Pazopanib, will be next in our pipeline.

These clinical studies owe much to our understanding of the basic biological mechanisms of autopahgy described by Dr. Ohsumi. His work has brought biology and medicine closer to finding treatments for chronic and deadly diseases.

Nobel prize-winning autophagy research laid groundwork for potential Parkinson's treatment

Forbes article on this topic
 

This piece was published last week as well ...

http://www.forbes.com/sites/carmendr.../#1636ce725a50

Best, Debi